{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008446","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2023-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.351310+00:00","generated_at":"2026-06-07T21:47:24.069891+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO","bullets":["One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.","One-time grant to Carlos Trujillo (CFO): $50,000 cash and options to purchase 85,000 shares at $2.18/share.","Options vest 50% on grant date (Nov 20, 2023) and 50% on one-year anniversary.","Grants made under the PharmaCyte Biotech 2022 Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008446","json":"https://secwatch.observer/filing/0001683168-23-008446.json","markdown":"https://secwatch.observer/filing/0001683168-23-008446.md","text":"https://secwatch.observer/filing/0001683168-23-008446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/0001683168-23-008446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:47:24.069891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}